| |
Scientific innovation in ligand targeting has spurred the development of many different types of radiopharmaceuticals (RPs) with a wide range of clinical uses. As those uses have grown, developers of RP products are faced with a regulatory environment that can be a challenge to navigate. We have a roadmap – read our guide for the details. Learn more. Premier Research. Built for Biotech℠ 
|
|
Today’s Big NewsNov 8, 2023 |
| By Nick Paul Taylor Xencor and CytomX Therapeutics have taken a scalpel to their pipelines, stopping work on an ex-AbbVie antibody-drug conjugate and pulling back from a co-development deal with Genentech to focus cash on other projects. |
|
|
|
By James Waldron Lumos Pharma's stock jumped this morning as a successful phase 2 trial maintained the Texan biotech’s hopes of bringing the first oral drug for pediatric growth hormone deficiency to market. |
By James Waldron A year after Lyell Immunopharma lost a $1 billion biobucks partnership with GSK, the cell therapy biotech is offloading a quarter of its staff and deprioritizing some earlier-stage research to extend funding into 2027. |
Sponsored by Resilience US, Inc. Digital twins can help biomanufacturing organizations spot and avoid failures that lead to costly delays. Explore this article to find out how. |
By Annalee Armstrong Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty opportunities from a recently acquired company—among other cost-cutting measures. |
Sponsored by IQVIA Greg Lever, Director within the IQVIA Applied Data Science Center, reveals how modeling technology is being used to unlock value and enhance the experience of trial participants. |
By Nick Paul Taylor Durect and investors have reached radically different conclusions about phase severe alcohol-associated hepatitis 2 data. The biotech hailed “remarkable” results, on a secondary goal, in a subpopulation, but failed to persuade investors to look past the failure of the primary endpoint, causing its stock to sink. |
By Nick Paul Taylor A press release has landed Daiichi Sankyo in hot water in the U.K. Pharma’s self-regulatory body found Daiichi prejudiced patient safety by failing to reference a contraindication, leading it to conclude that the Japanese drugmaker had brought discredit on the industry. |
By Andrea Park Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development—may now be a bit easier. |
By Heather Landi Building on its One Medical deal, Amazon is now offering a One Medical for Prime membership, including 24/7 virtual care, for $9 per month, or $99 a year. |
By Ben Adams It’s all the rage for superhero films: Bring together several fan favorite celebrities into one cinematic event. Pfizer is following Marvel and DC’s lead, bringing together its five most recent COVID commercial celebrities for a new ad promoting its booster. |
By Fraiser Kansteiner Armed with dwarfism med Voxzogo and hemophilia A gene therapy Roctavian, BioMarin recently turned a corner into profitability after many years operating at a loss. Now, the drugmaker has reportedly garnered the attention of activist investor Elliott Management. |
By Conor Hale Recor Medical's renal denervation approach tackles high blood pressure that hasn’t responded to medications or changes in lifestyle. |
Fierce podcasts Don’t miss an episode |
| While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more. |
|
|---|
|
|
Webinar Watch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Edison Ballroom, New York City |
|
|
| |
|
